shutterstock_mitochondria_Web-824x549.jp

ABOUT US

A World-Changing Discovery

Discovered and made in the USA🇺🇸

CoR Technology works on the Electron Transport Chain in mitochondria. 

It not only in the center of converting nutrition for increasing ATP production to provide the vital energy for cellular functions, but also works as a inducer to heat shock response network, the cell-singling pathways. Heat shock /chaperone proteins responsible for the refolding, repair and recycling of damaged proteins 

 

This innovative approach to preventing, delaying, and treating human degeneration can potentially slow or reverse the aging process! https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4779179/

 

70% of human diseases are related to mitochondrial dysfunction. 

 

CoR is now in the business development stage of pharmaceutical and nutraceutical therapeutic for human and animal degeneration diseases.

 

 

CoR TECHNOLOGY

CoR --- Cofactor R

The World's 4th Organic Redox Cofactor 

 A new cofactor that has been proven to be the most effective 
 

CoR4Mito Inc has discovered and identified CoR, a new and unique transmembrane oxidoreductase that acts on a sulfur group of donors, with FAD as the Carrier/ Acceptor. This enzyme catalyzes the transfer of electrons from one molecule to another in the mitochondria. 

CoR involves the Phase Transfer Property, transferring 2 electrons and multiple complicated catalyzed redox reactions including catalysis carbohydrate, fatty acid, and amino acid.

The required physiological Carrier/Acceptor of CoR is FAD. FAD is a more energetic oxidizing agent than NAD.

In contrast, PQQ,  the world’s 3rd redox cofactor, has not yet identified its physiological carrier/acceptor even after eighty years of study.

Lab Work
 
Handshake
Marble Surface

Investors

CoR Technology presents a new medical frontier. We are currently seeking new funding for advancing our research and development needs.

  • The worldwide market has been secured

  • The company has filed a worldwide IP to protect CoR’s market.

  • It is a solution for all mitochondrial dysfunction diseases, including aging-related diseases and more.

  • CoR Technology was discovered from human study cases already, and then backward to prove scientific evidence, which is different from traditional drug discovery.

Marble Surface

Partners

We are currently seeking strategic partners to further develop its unique, innovative intellectual property. The company has already established collaborative relationships with individual partners and universities to allow for more study and advancement in CoR Technology. 

At this time, CoR4Mito Inc utilizes a virtual corporate model deployment strategy for its core intellectual property. The company is seeking to build relationships in order to further advance the development of its IP CoR Technology into the broader markets of drug development, supplements, food additives, nutrition, dietary foods, and more.

Marble Surface

Licensing

CoR Technology’s unique, innovative IP proposes a groundbreaking and globalized pharmaceutical and nutraceutical composition.  

 

The company is open to exploring and entering into licensing agreements.

 

Welcome to contact us for further questions and information. 

MEET OUR TEAM

 

Shaoyun Liu

  • LinkedIn

Founder and CEO

Iwao Ojima, Ph.D.

Scientific Advisory

Peter G. Espina

  • LinkedIn

Strategic Business Advisor

Jerome Liang, Ph.D.

Scientific Advisory

Michael Jin

Legal Consultant 

Shanni Zhou

  • LinkedIn

Accountant

Affiliations

 

CONTACT US

1333 Stony Brook Rd, Stony Brook, NY 11790

  • LinkedIn
  • Facebook

CoR4Mito Inc.

Long Island High-Technology Incubator of Stony Brook University

25 Health Science Drive

Mail Box: 410

Stony Brook NY 11790

Phone: (631) 292-9008

Fax: (631) 621-0259

drliu@mitoliu.com

© CoR4Mito Inc. all rights reserved